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The effect of  ivermectin® on fertility, 
fecundity and mortality of Anopheles arabiensis 
fed on treated men in Ethiopia
Wondemeneh Mekuriaw1,6* , Meshesha Balkew2, Louisa A. Messenger3, Delenasaw Yewhalaw4,5, 
Adugna Woyessa1 and Fekadu Massebo6
Abstract 
Background: Insecticide resistance is a growing threat to malaria vector control. Ivermectin, either administered to 
humans or animals, may represent an alternate strategy to reduce resistant mosquito populations. The aim of this 
study was to assess the residual or delayed effect of administering a single oral dose of ivermectin to humans on the 
survival, fecundity and fertility of Anopheles arabiensis in Ethiopia.
Methods: Six male volunteers aged 25–40 years (weight range 64–72 kg) were recruited; four of them received a 
recommended single oral dose of 12 mg ivermectin and the other two individuals were untreated controls. A fully 
susceptible insectary colony of An. arabiensis was fed on treated and control participants at 1, 4, 7, 10 and 13 days post 
ivermectin-administration. Daily mosquito mortality was recorded for 5 days. An. arabiensis fecundity and fertility were 
measured from day 7 post treatment, by dissection to examine the number of eggs per mosquito, and by observing 
larval hatching rates, respectively.
Results: Ivermectin treatment induced significantly higher An. arabiensis mortality on days 1 and 4, compared to 
untreated controls (p = 0.02 and p < 0.001, respectively). However, this effect had declined by day 7, with no significant 
difference in mortality between treated and control groups (p = 0.06). The mean survival time of mosquitoes fed on 
day 1 was 2.1 days, while those fed on day 4 survived 4.0 days. Mosquitoes fed on the treatment group at day 7 and 
10 produced significantly lower numbers of eggs compared to the untreated controls (p < 0.001 and p = 0.04, respec-
tively). An. arabiensis fed on day 7 on treated men also had lower larval hatching rates than mosquitoes fed on days 10 
and 13 (p = 0.003 and p = 0.001, respectively).
Conclusion: A single oral dose of ivermectin given to humans can induce mortality and reduce survivorship of An. 
arabiensis for 7 days after treatment. Ivermectin also had a delayed effect on fecundity of An. arabiensis that took 
bloodmeals from treated individuals on day 7 and 10. Additional studies are warranted using wild, insecticide-resist-
ant mosquito populations, to confirm findings and a phase III evaluation among community members in Ethiopia is 
needed to determine the impact of ivermectin on malaria transmission.
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Background
Malaria is a disease transmitted by female Anopheles 
mosquitoes, caused by protozoan parasites of the genus 
Plasmodium. The disease predominately occurs in 
tropical and sub-tropical regions and remains a major 
public health problem. Most malaria cases in 2017 
occurred in the World Health Organization (WHO) 
African Region (92%), followed by the WHO South-East 
Asia Region (5%) and the WHO Eastern Mediterranean 
Region (2%). Of the 87 countries reporting indigenous 
malaria cases in 2017, 15 countries (all in sub-Saha-
ran Africa) and India carried 80% of the global malaria 
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burden. Malaria is estimated to have decreased by 20% in 
20 countries, mainly due to the wide use of vector control 
interventions, and increased with a similar magnitude in 
another 20 countries between 2016 and 2017 [1].
Current malaria vector control programs mainly rely 
on the use of chemical insecticides from five classes [2]. 
However, the  development of insecticide resistance [3, 
4] and behavioural changes, including early and outdoor 
biting activities [5], may jeopardize the effectiveness of 
malaria vector control interventions. In Ethiopia, vec-
tor behavioural changes, such as behavioural avoidance, 
feeding on animals, resting outdoors away from indoor 
treated surfaces, and feeding upon humans when they 
are not protected, all contribute to sustaining residual 
malaria transmission [6]. The zoophagic tendency of 
Anopheles arabiensis [7] presents an opportunity to con-
trol this species by treating cattle with ivermectin and it 
is an important option to target zoophagic mosquitoes.
To achieve malaria elimination before 2030, as set by 
the WHO [8], innovation of vector control tools to coun-
teract the emergence of drug and insecticide resistance is 
fundamental [9]. For this reason, ivermectin is receiving 
more attention as a potential tool to be used for malaria 
control [9–11]. This drug has been used since the 1980s 
for animal health to control parasitic diseases, includ-
ing cattle onchocerciasis [12, 13], lymphatic filariasis 
[14], and scabies and lice [15, 16]. Evidence for the effi-
cacy of ivermectin to reduce Anopheles survivorship 
and Plasmodium sporozoite rate is growing. Mass drug 
administration of ivermectin in southeastern Senegal 
for onchocerciasis and lymphatic filariasis dramatically 
affected the density of malaria vectors and reduced the 
proportion of Plasmodium falciparum infectious mos-
quitoes [17]. Furthermore, the survivorship of Anoph-
eles gambiae sensu stricto (s.s.) that ingested blood of 
humans treated with 200 μg/kg ivermectin was reduced 
significantly after 1  day of treatment [18]; however, this 
effect was not apparent 14  days post-ingestion. This 
might be because ivermectin and/or its metabolites are 
removed from plasma over 12 days after treatment [19]. 
Even a single dose of ivermectin in small concentrations, 
can have a deleterious effect on mosquitoes before they 
become infectious and can reduce survival [18, 20]; iver-
mectin-exposed mosquitoes are less likely to transmit 
Plasmodium parasites due to a shift in Anopheles popula-
tions to younger mosquitoes [10].
The implementation of ivermectin could contribute 
to insecticide resistance management. The occurrence 
of cross-resistance to ivermectin from currently used 
insecticides is less likely as its mechanism of action (inhi-
bition of glutamate-gated chloride channels) is differ-
ent [21]. However metabolic resistance could still affect 
the impact of  ivermectin on mosquito mortality [22]. 
Treatment of cattle or humans with ivermectin, may rep-
resent a viable complementary vector control strategy. 
The aim of this study was to assess the effect of adminis-
tering a single oral dose of ivermectin to humans on mor-
tality, fecundity and fertility of a laboratory colony of An. 
arabiensis in Ethiopia.
Methods
Study area, design and participants
This study was conducted from July 2017 to October 2017 
at the Tropical and Infectious Diseases Research Centre, 
Jimma University in Sekoru, Oromia region (7.922305° N, 
37.395320° E). The research centre is 246 km South-West 
of Addis Ababa, situated at an altitude of 1684 m above 
sea level. Six volunteer males aged 25–40 years, weighing 
between 64 and 72 kg were recruited from Sekoru village, 
after receiving informed consent. The dosage of ivermec-
tin given to volunteer range from 166.7 to 187.5  µg/kg. 
The volunteers were assigned randomly to either treat-
ment or control groups using a lottery method. Four of 
them received a recommended single oral dose of 12 mg 
ivermectin for these weights and the other two individu-
als did not receive the drug (untreated controls). The 
entomology technicians (providing mosquitoes for feed-
ing and performing mosquito  dissections) were blinded 
to the treatment and control groups. The drug was 
obtained from the Ministry of Health, donated by the 
Mectizan donation program for onchocerciasis elimina-
tion in Ethiopia.
Experimental procedure
Mosquito rearing in the laboratory
An insecticide-susceptible colony of An. arabien-
sis (Debre Zeit: DZ) [23], reared under standard con-
ditions of 27 ± 2  °C, 70 ± 10% relative humidity and 
12  h/12  h  day/night cycles, was used for this experi-
ment. Larvae were reared in plastic trays in distilled 
water and were provided a diet of ground  Tetramin® 
fish food. Pupae were collected in cups and placed in 
30 × 30 × 30  cm cages. Emerging adults were provided 
with 10% sugar solution for 3–5 days.
Mosquito feeding
Prior to human feeding, female 3–5  day-old, An. ara-
biensis were starved of sugar solution for 4  h. Twenty-
four hours after ivermectin ingestion, human volunteers 
exposed their right arm to 90–100 starved female An. 
arabiensis inside cages. A total of six cages (four for 
the ivermectin group, two for the untreated control) 
were used. Mosquitoes were allowed to feed for 30 min. 
Unfed and fully un-engorged mosquitoes were removed 
from the cages using mouth aspirators. Then, fully fed 
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mosquitoes were maintained on 10% sugar solution for 
5 days. Mosquito mortality was recorded every 24 h for 
those 5  days. The feeding experiment was repeated at 
days 4, 7, 10 and 13 post-ivermectin treatment using dif-
ferent batches of mosquitoes, following the same proce-
dure (Fig. 1).
Mortality estimation of Anopheles arabiensis
Daily mortality of mosquitoes was monitored for 5 days 
after feeding for both treatment and control groups 
in each round. Dead mosquitoes were recorded and 
removed from the cages every day. New batches of An. 
arabiensis were used in each replicate. Mosquitoes were 
considered dead if they were lying on the bottom of the 
cage and unable to move. If a mosquito was unable to fly 
yet it was able to stand on its legs, it was considered alive 
[24].
Fecundity estimation of An. arabiensis
Mosquito fecundity was measured starting day 7 post 
treatment because of the high mortality rate in the early 
days of follow-up. Mosquitoes were offered a blood meal 
from a volunteer on day 7, 10 and 13. To determine fecun-
dity, 80 gravid mosquitoes from treatment groups and 40 
from the control group were dissected on the fourth day 
after their  blood meal using a dissecting microscope in 
round 3, 4 and 5. For dissection, female mosquitoes were 
anaesthetized using chloroform, placed on a clean micro-
scope slide in a drop of distilled water. The thorax of a 
mosquito was gently grasped by a dissecting needle and 
the last two abdominal segments were gently pulled away 
using another dissecting needle to count the number of 
eggs (partially-formed eggs were  also counted) in both 
ovaries.
Fertility estimation of An. arabiensis
In each round an additional 80 gravid An. arabiensis 
from the treatment group and 40 from the control group 
were gently transferred to  individual 1.5  ml Eppendorf 
tubes, containing a moist triangular piece of Whatman 
No. 1 filter paper with air holes in the cap and base, using 
a mouth aspirator. Laid eggs from the experimental and 
control groups were reared in separate plastic cups filled 
with distilled water. Hatched larvae were supplied with 
fish food  (TetraMin®) daily in larval pans. The number of 
newly emerged larvae were recorded. Eggs that could not 
develop into larvae up to day 7 were considered infertile.
Data analysis
Data were recorded in appropriately designed forms, 
entered into Microsoft excel for data cleaning and 
exported to SPSS version 16 and R version 3.4.4 software 
for analysis. Analysis of variance were used to compare 
mean mortality, fecundity and fertility of mosquitoes 
Fig. 1 Flow chart of the mosquito feeding procedures
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between treatment and control groups as well as among 
individual experimental group replicates. Descriptive sta-
tistics were used to calculate feeding rates of mosquitoes 
and hatching rates of eggs. Survivorship of mosquitoes 
was analysed using Kaplan–Meier survival curves. Mor-
tality of mosquitoes was standardized and pooled prior 
to data analysis.
Results
Effect of ivermectin on Anopheles arabiensis mortality
The number of An. arabiensis exposed to feed on 
humans were 2965 and out of this 2465 mosquitoes 
became fully engorged. The feeding rate of mosquitoes 
was 83.1% and an average of 493 mosquitoes were used 
per replicate. There were no significant differences in 
mosquito feeding rates between treatment and control 
groups (82.5% and 84.5% average feeding rates, respec-
tively p = 0.355). Overall feeding rates of mosquitoes at 
different feeding days are shown in Table  1. The mean 
mortality rate during the 5-day follow-up was high on 
day 1, 4 and 7 post-treatment compared to the controls. 
The mean daily mortality of mosquitoes fed on days 10 
and 13 was similar to the control mortality (Table 2 and 
Fig. 2).  
The mean number of dead An. arabiensis, after feeding 
on ivermectin-treated individuals on day 1 post admin-
istration, was 13.8; this was significantly higher than 
mortality after feeding on control individuals (3.7 dead; 
p = 0.02), during 5 days of follow-up (Table 2). Similarly, 
the mean mortality of An. arabiensis fed on treated vol-
unteers 4 days post ivermectin treatment was also signifi-
cantly different from controls (p < 0.001). There was no 
difference in mosquito mortality between treatment and 
control groups from day 7 post ivermectin administra-
tion onwards (Table 2).
The effect of ivermectin on mean 5-day mortality of 
An. arabiensis between different feeding intervals var-
ied among treatment groups and controls, according to 
a one-way ANOVA and a post hoc multiple compari-
sons test (Fig.  3). Mean daily mortality of An. arabien-
sis fed on ivermectin treated volunteers on day 1 and 
day 4 were not significantly different (p = 0.73) (Fig.  3). 
By comparison, mean daily mortality of An. arabien-
sis fed on day 1 was significantly higher than those feed 
Table 1 Feeding rates of mosquitoes at different feeding times
DAT days after treatment
Feeding day Treatment Control
Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 1 Replicate 2
1DAT 74.00 80.00 81.11 86.67 83.00 77.00
4DAT 80.00 91.00 73.00 81.00 86.00 82.00
7DAT 87.00 86.00 79.00 82.00 94.00 83.00
10DAT 90.00 86.00 79.00 77.00 86.00 85.00
13DAT 87.00 83.16 94.44 72.00 92.00 78.00
Table 2 Mean daily mortality of  An. arabiensis fed on  treated or  control volunteers at  different feeding days 
after ivermectin administration and follow-up for five consecutive days
Feeding day: the day when An. arabiensis mosquitoes took a bloodmeal from ivermectin treated or control volunteers after drug administration
CI confidence interval, DAT days after treatment, N number of An. arabiensis
Feeding day Exposure Mosquito, N Mean daily 
mortality
95% CI for mean P value
Lower bound Upper bound
1DAT Treatment 76 13.83 7.84 19.81 0.02
Control 80 3.70 1.82 5.59
4DAT Treatment 81 11.19 8.52 13.87 0.00
Control 84 3.46 1.35 5.57
7DAT Treatment 84 4.74 3.57 5.91 0.06
Control 89 2.85 0.99 4.70
10DAT Treatment 83 2.76 2.26 3.25 0.38
Control 86 2.33 1.23 3.43
13DAT Treatment 81 2.52 1.45 3.59 0.80
Control 85 2.73 1.33 4.14
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on days 7, 10 and 13 (p < 0.001). In addition, mean daily 
mortality of An. arabiensis fed on day 4 post treatment, 
was significantly different from day 7 (p = 0.011, 95% CI 
0.9824–11.92), day 10 (p < 0.001, 95% CI 2.96–13.90) and 
day 13 (p < 0.001, 95% CI 3.20–14.15). However, mean 
daily mortality rates of An. arabiensis fed on ivermectin-
treated volunteers on days 7, 10 and 13 were not statisti-
cally different (p = 0.900, 95% CI 3.49–7.45).
Effect of ivermectin on An. arabiensis fecundity
The effect of ivermectin on An. arabiensis fecundity on 
days 1 and 4 after treatment was not assessed due to 
high mortality of An. arabiensis during this period. The 
mean number of eggs laid by An. arabiensis, which fed 
on treated volunteers on day 7, was 42.24 ± 6.60, com-
pared to 110.05 ± 4.81 in the control group (p < 0.001). 
The mean number of eggs laid by An. arabiensis, which 
took blood meals from treated volunteers on day 10 post 
ivermectin administration was also significantly differ-
ent compared to the control group (p = 0.04). However, 
ivermectin did not have a significant effect on fecundity 
of An. arabiensis after day 13 post drug  administration 
(p = 0.34) (Table 3).
The effect of ivermectin on fecundity of An. arabiensis 
were compared between days 7, 10 and 13 after treat-
ment. The mean number of eggs laid by An. arabiensis, 
which fed on treated volunteers on day 7 was significantly 
different compared to day 10 (mean difference: 52.7; 95% 
CI 41.9–63.9; p < 0.001) and day 13 (mean difference: 
Fig. 2 The cumulative mortality rate of An. arabiensis during 5-days of follow-up at different feedings days, post-ivermectin treatment, July 2017, 
Sekoru. *Five rounds of mean mortality of mosquitoes in the control group
Fig. 3 Pairwise comparisons of mean daily mortality of An. arabiensis 
at different feeding days after ivermectin administration. DAT days 
after treatment. Mortality was not significantly different between 
feeding days, where mean difference confidence intervals cross the 
middle construction line
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72.3; CI 61.2–83.5; p < 0.001). There was also a significant 
difference in mosquito fecundity between days 10 and 13 
(mean difference: 19.6; 95% CI 8.5–30.7; p < 0.001).
Effect of ivermectin on An. arabiensis fertility
The effect of ivermectin on An. arabiensis fertility on 
days 1 and 4 post ivermectin treatment was also not 
assessed. Mean hatching rates of eggs, laid from mosqui-
toes fed on treated volunteers compared to the control 
group, were 73.8% vs. 91.3% on day 7, 88.6% vs. 91.9% 
on day 10 and 90.5% vs. 92.5% on day 13. Significant dif-
ferences in hatching rates between An. arabiensis, fed on 
treated vs control individuals, were observed on day 7 
(p = 0.03) but not days 10 and 13 (p = 0.07 and p = 0.34, 
respectively).
Mean hatching rate of eggs from An. arabiensis, which 
took a blood meal on day 7 after ivermectin administra-
tion, was significantly lower compared to day 10 (mean 
difference: 14%; 95% CI 6.8–23.45; p = 0.03) and day 13 
(mean difference: 16%; 95% CI 8–25.3; p < 0.001). How-
ever, the effect of ivermectin on fertility was not sig-
nificant between days 10 and 13 post treatment (mean 
difference: 1.9%; 95% CI 6.8–10.6; p = 0.82) (Table 4).
Effect of ivermectin on An. arabiensis survival
The effect of ivermectin on An. arabiensis survival was 
assessed for five consecutive days post feeding on treated 
or control participants. All live mosquitoes on day 5 were 
considered as censored.
The mean survival time of An. arabiensis, which blood 
fed from ivermectin treated volunteers on day 1 post 
treatment was 2.1, compared to 5.5 in the control group 
(p < 0.001) (Table  5). Statistically significant differences 
in mean survival time of exposed An. arabiensis, com-
pared to control mosquitoes, were also observed on day 
4 (mean survival days: 4.02, 95% CI 3.69–4.36; p < 0.001) 
and day 7 (mean survival days: 5.06; 95% CI 4.73–5.39; 
p = 0.01), post treatment. Otherwise no statistically sig-
nificant difference was demonstrated for days 10 and 13 
(Table 5).
As shown in Fig.  4, the majority of An. arabiensis 
that fed on treated volunteers on day 1 post ivermec-
tin administration died within 2  days. By comparison, 
most An. arabiensis, which took a blood meal from 
treated volunteers on day 4 post-treatment, died within 
4 days.
Table 3 Mean number of eggs per mosquito fed on ivermectin treated and non-treated volunteers at different feeding 
times
Feeding day: the day when An. arabiensis mosquitoes took a bloodmeal from ivermectin treated or control volunteers after drug administration
SD standard deviation, SE standard error, CI confidence interval, N number of gravid An. arabiensis
Feeding day Exposure Mosquito N Mean no. eggs/
ovary
95% CI for mean P-value
Lower bound Upper bound
7DAT Treatment 80 42.24 31.74 52.73 < 0.001
Control 40 110.05 66.85 153.25
10DAT Treatment 80 94.99 84.98 105 0.04
Control 40 112.35 46.91 177.79
13DAT Treatment 80 114.6 110.31 118.89 0.34
Control 40 110.85 52.4 169.3
Table 4 Mean hatching rate of  eggs from  An. arabiensis mosquitoes fed on  ivermectin treated and  non-treated 
volunteers at different feeding days
SD standard deviation, SE standard error, CI confidence interval
Feeding day Exposure Mean no. of eggs 
laid
% mean hatching 95% CI for mean P-value
Lower bound Upper bound
7DAT Treatment 44 73.85 62.37 85.33 0.03
Control 110 91.29 78.73 103.85
10DAT Treatment 97 88.62 86.15 91.09 0.07
Control 119 91.9 77.63 106.17
13DAT Treatment 116 90.53 87.5 93.56 0.34
Control 122 92.51 90.82 94.2
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Discussion
In this study, a single oral dose of ivermectin induced An. 
arabiensis mortality and reduced fecundity and fertil-
ity after feeding on treated men, compared to controls. 
Previous studies conducted on the effects of ivermectin 
on different disease vectors documented that ivermectin 
reduced the survivorship of Anopheles stephensi, Aedes 
aegypti, Culex pipiens and Culex quinquefasciatus [25]. 
Table 5 Mean survival time of mosquitoes during 5-days of follow-up at different feeding days
Feeding day Exposure Mean survival time 
(days)
95% CI X2 P-value
Lower bound Upper bound
1DAT Treatment 2.13 1.80 2.46 117.1 < 0.001
Control 5.53 5.30 5.75
4DAT Treatment 4.02 3.69 4.36 49.9 < 0.001
Control 5.60 5.39 5.80
7DAT Treatment 5.06 4.73 5.39 6.1 0.01
Control 5.66 5.47 5.85
10DAT Treatment 5.47 5.20 5.74 0.0 0.87
Control 5.56 5.34 5.77
13DAT Treatment 5.63 5.41 5.84 0.02 0.89
Control 5.65 5.45 5.85
Fig. 4 Kaplan–Meier survival curve of An. arabiensis during 5 days of follow-up after different feeding days post ivermectin treatment
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The majority of tested mosquitoes, which fed 1 day post 
treatment died within 2  days and 93% mortality was 
recorded on day 5 post-ingestion. In agreement with the 
present study, results from Kenya showed that nearly half 
of blood fed An. gambiae from the ivermectin group died 
on the second day and 90% died on day 6, compared to 
9% mortality in the control group on day 6 [26]. In addi-
tion, a dose of 300  μg/kg ivermectin per day given for 
3 days to malaria patients can reduce mosquito survival 
for at least 28 days after treatment [27]. Multiple studies 
support the observation that mass drug administration 
of ivermectin reduces the survivorship of mosquitoes 
[28, 29]. In West Africa, following ivermectin mass drug 
administration (MDA), survival of An. gambiae declined 
by more than 33% for 6 days, with reductions of sporozo-
ites by 77% in the following 2 weeks; and a reduction in 
parity rate was also observed [30]. Ivermectin-containing 
blood meals have also been shown to reduce the survi-
vorship of principal malaria vectors in different parts of 
the world [18, 20, 28, 29, 31–33].
The present study revealed that mosquito survival was 
significantly reduced after the ingestion of ivermectin 
from treated humans on 1 and 4  days after treatment. 
Mortality of mosquitoes started to decrease from day 7. 
Therefore, day 7 could be the re-dosing time of ivermec-
tin in this context. This is one pharmacological strategy 
recommended by the WHO to increase the efficacy of 
ivermectin [9]. However, this is hard to do logistically 
in the community unless a longer lasting formulation of 
ivermectin is developed in the future. The death rate of 
mosquitoes on day 10 and 13  day after treatment were 
similar to the control group, which may be attributed to 
the pharmacokinetics of ivermectin in the human body. 
Since the concentration of ivermectin and/or its metabo-
lites are excreted in faeces every day, the residual concen-
tration found in the plasma is also reduced day to day [16, 
34].
The current study revealed that the number of eggs 
observed in the mosquitoes’ ovaries was reduced after 
the ingestion of ivermectin on 7 and 10 days after treat-
ment. Studies conducted on Anopheles aquasalis doc-
umented a similar effect of ivermectin on mosquito 
fecundity [35]. In addition to this, a study by Gardner 
et al. [31] showed a reduction in fecundity of Anopheles 
quadrimaculatus, exposed to 24 µg/kg ivermectin. These 
and the current study findings indicate that ivermectin 
can reduce mosquito density, prior to completion of the 
gonotrophic cycle [36].
Ivermectin also impacted mosquito fertility at day 
7 post-treatment, in agreement with previous studies 
done on cattle, which also showed reduced fertility [29]. 
The effect of ivermectin on fertility of Ae. aegypti, Aedes 
albopictus, and Cx. quinquefasciatus has been reported 
[37]. Furthermore, Gardner et  al. [31] also showed the 
effect of 24  µg/kg ivermectin on hatching rate of An. 
quadrimaculatus mosquitoes. All of these physiological 
effects contribute to the reduction of vector population 
density.
This study has several strengths and limitations. The 
study was conducted using susceptible colony mosqui-
toes and, therefore, these findings cannot yet be directly 
extrapolated to wild mosquito populations. Additional 
studies, in areas characterized by different insecticide 
resistance intensities and underlying mechanisms are 
warranted to validate these phenomena. However, the 
study showed the delayed effect of a  single oral dose of 
ivermectin used to treat onchocerciasis on the mortality, 
fertility and fecundity of mosquitoes, which is considered 
as the strength of the study.
Conclusions
A single oral dose of ivermectin provided to humans can 
induce mortality and reduce survivorship of An. ara-
biensis for 7  days after treatment. It also had a delayed 
effect on fecundity of An. arabiensis that took blood meal 
from treated individuals on day 7 and 10 after ivermec-
tin administration. Moreover, a delayed effect on fertility 
was observed when An. arabiensis took blood meal from 
treated volunteers on 7  days after treatment. Together 
these effects demonstrated the potential for ivermectin to 
reduce An. arabiensis population densities.
Recommendations
The effect of ivermectin on wild population survival, 
fecundity, and fertility must be studied before pub-
lic health use. In addition, future studies are needed to 
investigate the delayed effects of ivermectin on survival, 
fecundity, and fertility of insecticide resistant mosquito 
populations in Ethiopia and in other malaria endemic 
countries.
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